Stock DGX QUEST DIAGNOSTICS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Quest Diagnostics Incorporated

Equities

DGX

US74834L1008

Healthcare Facilities & Services

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
134.3 USD -0.86% Intraday chart for Quest Diagnostics Incorporated +4.53% -2.63%
Apr. 25 Labcorp beats quarterly estimates on strong testing demand RE
Apr. 24 Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14,384 16,060 21,224 17,817 15,503 14,915 - -
Enterprise Value (EV) 1 17,962 18,917 24,364 21,482 19,683 18,982 18,351 18,093
P/E ratio 17 x 11.4 x 11.1 x 19.6 x 18.4 x 17.2 x 15.8 x 14.2 x
Yield 1.99% 1.88% 1.53% 1.69% - 2.15% 2.22% 2.26%
Capitalization / Revenue 1.86 x 1.7 x 1.97 x 1.8 x 1.68 x 1.58 x 1.53 x 1.48 x
EV / Revenue 2.32 x 2 x 2.26 x 2.17 x 2.13 x 2.01 x 1.88 x 1.8 x
EV / EBITDA 11.6 x 7.66 x 8.49 x 10.4 x 11 x 10.1 x 9.22 x 8.71 x
EV / FCF 21.3 x 11.9 x 13.3 x 16.3 x 22.8 x 21.2 x 16.8 x 14.6 x
FCF Yield 4.69% 8.39% 7.51% 6.12% 4.39% 4.72% 5.95% 6.86%
Price to Book 2.52 x 2.34 x 3.19 x 2.95 x - 2.18 x 2.01 x 1.83 x
Nbr of stocks (in thousands) 134,697 134,766 122,675 113,887 112,435 111,092 - -
Reference price 2 106.8 119.2 173.0 156.4 137.9 134.3 134.3 134.3
Announcement Date 1/30/20 2/4/21 2/3/22 2/2/23 2/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7,726 9,437 10,788 9,883 9,252 9,448 9,750 10,072
EBITDA 1 1,549 2,468 2,870 2,059 1,788 1,885 1,990 2,078
EBIT 1 1,220 2,107 2,462 1,742 1,457 1,515 1,611 1,715
Operating Margin 15.79% 22.33% 22.82% 17.63% 15.75% 16.04% 16.52% 17.02%
Earnings before Tax (EBT) 1 1,076 1,884 2,599 1,235 1,130 1,206 1,296 1,411
Net income 1 858 1,431 1,995 946 854 894.3 960.5 1,048
Net margin 11.11% 15.16% 18.49% 9.57% 9.23% 9.47% 9.85% 10.41%
EPS 2 6.280 10.47 15.55 7.970 7.490 7.823 8.520 9.427
Free Cash Flow 1 843 1,587 1,830 1,314 864 895.4 1,091 1,241
FCF margin 10.91% 16.82% 16.96% 13.3% 9.34% 9.48% 11.19% 12.32%
FCF Conversion (EBITDA) 54.42% 64.3% 63.76% 63.82% 48.32% 47.51% 54.83% 59.7%
FCF Conversion (Net income) 98.25% 110.9% 91.73% 138.9% 101.17% 100.12% 113.62% 118.39%
Dividend per Share 2 2.120 2.240 2.640 2.640 - 2.888 2.977 3.029
Announcement Date 1/30/20 2/4/21 2/3/22 2/2/23 2/1/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 2,744 2,611 2,453 2,486 2,333 2,331 2,338 2,295 2,288 2,366 2,395 2,365 2,330 2,426 2,479
EBITDA 1 659 660 515 504 407 431 473 464 420 436 487 484.3 462.6 459.6 504.6
EBIT 1 553 554 435 423 330 350 389 380 338 349 404.6 398.2 365.3 373.3 429.8
Operating Margin 20.15% 21.22% 17.73% 17.02% 14.14% 15.02% 16.64% 16.56% 14.77% 14.75% 16.89% 16.83% 15.68% 15.39% 17.34%
Earnings before Tax (EBT) 1 502 452 323 351 109 277 317 299 237 266 325 318.5 285 279.5 344.5
Net income 1 390 355 234 256 101 202 235 225 192 194 238 233.5 206.9 206.9 253.3
Net margin 14.21% 13.6% 9.54% 10.3% 4.33% 8.67% 10.05% 9.8% 8.39% 8.2% 9.93% 9.87% 8.88% 8.53% 10.22%
EPS 2 3.120 2.920 1.960 2.170 0.8700 1.780 2.050 1.960 1.700 1.720 2.083 2.063 1.834 1.861 2.285
Dividend per Share 2 0.6200 0.6600 0.6600 0.6600 0.6600 0.7100 0.7100 - - - 0.7322 0.7322 0.7322 0.7470 0.7744
Announcement Date 2/3/22 4/21/22 7/21/22 10/20/22 2/2/23 4/27/23 7/26/23 10/24/23 2/1/24 4/23/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 3,578 2,857 3,140 3,665 4,180 4,066 3,435 3,178
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.31 x 1.158 x 1.094 x 1.78 x 2.338 x 2.158 x 1.726 x 1.529 x
Free Cash Flow 1 843 1,587 1,830 1,314 864 895 1,091 1,241
ROE (net income / shareholders' equity) 16.5% 24.6% 28.4% 19.1% 14% 15.1% 14.9% 14.9%
ROA (Net income/ Total Assets) 7.51% 11.4% 13.2% 8.93% 6.36% 7.04% 7.31% 7.72%
Assets 1 11,417 12,590 15,091 10,593 13,430 12,701 13,140 13,574
Book Value Per Share 2 42.40 50.80 54.20 53.10 - 61.50 66.90 73.20
Cash Flow per Share 2 9.140 6.780 17.40 14.60 11.30 11.60 14.70 14.70
Capex 1 400 418 403 404 408 421 427 432
Capex / Sales 5.18% 4.43% 3.74% 4.09% 4.41% 4.45% 4.37% 4.29%
Announcement Date 1/30/20 2/4/21 2/3/22 2/2/23 2/1/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Quest Diagnostics Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
134.3 USD
Average target price
146 USD
Spread / Average Target
+8.77%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-2.63% 14.92B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-14.92% 84.68B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.30% 81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+10.92% 29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-12.71% 16.73B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-3.06% 16.36B
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
-3.97% 11.66B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
-1.42% 11.72B
PURE HEALTH HOLDING Stock Pure Health Holding
-31.75% 11.77B
DAVITA INC. Stock DaVita Inc.
+27.44% 11.71B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. DGX Stock
  4. Financials Quest Diagnostics Incorporated